TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06307652: A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure a

Sponsor: AstraZeneca · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 3850 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$5,374,416

Rescue Site Savings

+$3,535,800

Unlock Full NCT06307652 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06307652 Rescue Dossier →